CTI BioPharma Corp. (NASDAQ:CTIC) is scheduled to post its quarterly earnings results after the market closes on Monday, November 6th. Analysts expect CTI BioPharma Corp. to post earnings of ($0.32) per share for the quarter.

CTI BioPharma Corp. (NASDAQ:CTIC) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.60) by $0.63. CTI BioPharma Corp. had a negative return on equity of 418.99% and a negative net margin of 136.76%. The business had revenue of $22.23 million during the quarter. On average, analysts expect CTI BioPharma Corp. to post $-1.26 EPS for the current fiscal year and $-1.87 EPS for the next fiscal year.

Shares of CTI BioPharma Corp. (CTIC) traded down 0.63% during trading on Monday, hitting $3.14. The stock had a trading volume of 87,234 shares. The stock’s 50-day moving average is $3.25 and its 200-day moving average is $3.54. The stock’s market capitalization is $99.62 million. CTI BioPharma Corp. has a 12-month low of $2.70 and a 12-month high of $6.48.

Several brokerages recently issued reports on CTIC. ValuEngine cut CTI BioPharma Corp. from a “sell” rating to a “strong sell” rating in a research note on Wednesday, October 11th. Jefferies Group LLC began coverage on CTI BioPharma Corp. in a research note on Tuesday, September 12th. They issued a “buy” rating and a $7.50 price target for the company.

WARNING: “CTI BioPharma Corp. (CTIC) to Release Earnings on Monday” was posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/10/30/cti-biopharma-corp-ctic-to-release-earnings-on-monday.html.

In other CTI BioPharma Corp. news, Director Richard L. Love sold 14,600 shares of the business’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $3.21, for a total transaction of $46,866.00. Following the completion of the transaction, the director now directly owns 84,318 shares in the company, valued at $270,660.78. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 8.08% of the company’s stock.

About CTI BioPharma Corp.

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).

Earnings History for CTI BioPharma Corp. (NASDAQ:CTIC)

Receive News & Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related companies with MarketBeat.com's FREE daily email newsletter.